Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Cancer is a genetic disease – one that results from changes, known as mutations, to our DNA and genes.
When it comes to promoting cancer, not all mutations are equal. This is because cancer-causing mutations affect certain genes far more frequently than others.
One of these genes is known as MYC, which codes for the MYC protein. Over half of all cancers show changes to levels of MYC – a distinction that has led to it being referred to as one of the "hallmarks of cancer."
Because MYC is involved in so many different cancers, targeting it would be a promising strategy to stop the growth of cancer. However, to date, and despite extensive efforts, drugs developed to block MYC have failed in experimental models.
New findings by
Dr. Linda Penn, a Senior Scientist at the Princess Margaret Cancer Centre, have overcome this hurdle. Her latest work, published in
Cancer Cell, reveals a new way to target MYC – one that is based on new insights into how the MYC protein functions in the cell.
Along with her collaborators, Dr. Penn's team identified a protein – known as G9a, a histone H3K9-methyltransferase complex – that binds to and works together with the MYC protein to promote the growth of cancer.
"By identifying that MYC binds to G9a to repress the expression of specific genes, we have overcome a long-standing mystery in the field and identified a potential new anticancer target," says Dr. Penn.
"Importantly, we were able to show in various experimental and preclinical models that targeting G9a slows MYC-driven tumour growth. This is a major advancement because MYC has been declared 'undruggable' using traditional drug development approaches.
"Our work suggests that, by targeting a key partner protein of MYC, anticancer drugs for MYC-driven cancers could be developed."
This work was supported by the Canadian Institutes of Health Research, the Ontario Institute for Cancer Research, the Terry Fox Research Institute and The Princess Margaret Cancer Foundation. LZ Penn holds a Tier 1 Canada Research Chair in Molecular Oncology. C Arrowsmith holds a Tier 1 Canada Research Chair in Structural Proteomics.